EURAMOS is the European and American
Group. The study was founded in 2001.
This website contains information about Osteosarcoma and the current EURAMOS I Trial.
To read more about EURAMOS click here.
If you have any questions regarding the EURAMOS 1 trial or any difficulties using this website, please contact firstname.lastname@example.org
We would like to welcome to the EURAMOS-1 team Babasola Popoola, as our new EURAMOS-1 Data Manager at the MRC CTU at UCL. Please do not hesitate to contact Babasola with any queries on data and follow ups.
Release of the new EURAMOS-1 Protocol (version 4.0 dated 12 February 2015). This amendment has been approved in the UK (MREC approval on 27.04.2015 and MHRA approval on 11.08.2015). This amendment was an update of the end of trial definition to comply with current legislation. To obtain a copy of this protocol please click here or email email@example.com
EURAMOS-1 Good Responders paper has been published in the JCO on the 1
2015. It can be accessed by clicking here
EURAMOS-1 Registration Paper Published in Annals of Oncology
The EURAMOS-1 Registration Paper has been published in Annals of Oncology and can be accessed by clicking here
Bringing Medicine to Life
Images from the Art Project are on
permanent display at the Wellcome Trust 'Medicine Now' Gallery, located
on the first floor of Wellcome Collection Conference Centre, 183 Euston
Click here to read more about the Art Project.
A project inspired by the MRC Clinical Trials Unit in collaboration
with Dr Martha Perisoglou in the University College Hospital, London.
New Applicant Countries
EURAMOS I is no longer accepting applications from new countries wishing to join the trial but welcomes expressions of interest from national representatives wishing to participate in future EURAMOS collaborations. Please contact us on firstname.lastname@example.org
Scandinavian Sarcoma Group (SSG)
The Scandinavian Sarcoma Group (SSG) comprises the Scandinavian countries (Denmark, Finland, Iceland, Norway and Sweden) with a population of about 25 million people.
Since 1979, SSG has performed three non-randomized neo-adjuvant chemotherapy trials for high-grade osteosarcoma localized to the extremities.